乳腺癌患者使用卡维迪洛的风险导向心脏保护 (CCT指南):一期随机临床试验
Wonyoung Jung1, Rebecca A Hubbard2, Amanda M Smith1
1Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Breast cancer research and treatment
|April 2, 2025
概括
使用卡维迪洛的风险导向方法可以应用于接受治疗的乳腺癌患者,以评估心脏保护. 需要进一步的策略来优化活跃癌症患者的非治疗干预试验.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 乳腺癌治疗方法,包括 antracycline 和 trastuzumab,增加心脏毒性风险.
- 在这些患者心脏保护的风险导向策略需要进一步调查.
- 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110.0. 试验注册:NCT04023110. 试验注册:NCT04023110. 试验注册:NCT04023110. 试验注册:NCT04023110. 试验注册:NCT04023110.
研究的目的:
- 在乳腺癌患者中测试风险导向心脏保护策略的可行性,安全性和耐受性.
- 为了评估心脏毒性风险评分对患者分层的应用.
- 评估卡维迪醇在降低高风险患者心脏毒性的疗效.
主要方法:
- 一期,单中心,随机试验,涉及68名乳腺癌患者 (I-III阶段).
- 患者被分为低或高心脏毒性风险组,使用内部验证的得分.
- 患有高风险的患者被随机分配给接受卡维迪洛或常规护理,结果在24个月内进行评估.
主要成果:
- 68名患者被纳入;49名低风险,19名高风险. 13名高风险患者接受了卡维迪洛,6人接受了常规护理.
- 在每天两次服用6.25毫克的中位数剂量下,卡维迪醇的坚持率为93%.
- 各组的不良事件相似;一个低风险患者患有心脏功能障碍. 在二次结果中没有实质性的差异.
结论:
- 在患有活跃乳腺癌的患者中,以风险为导向的心脏保护策略是可行的.
- 作为这一策略的一部分,可以安全地给高风险患者服用卡维迪洛尔.
- 对于患有活跃癌症的患者,非治疗干预试验设计的优化是必要的.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
393
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
393
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284


